[Ifosfamide versus ifosfamide + CCNU in the treatment of inoperable small cell carcinoma of the lung. A clinical study].
55 selected patients with inoperable small cell carcinoma of the lung have been induced in a randomized prospective trial in order to compare the efficacy of ifosfamide monotherapy with the combination of ifosfamid + CCNU. Initially a control group, treated with symptomatic therapy only, was also included but preliminary analysis revealing that results were unfavourable in comparison to those of the chemotherapy group; this treatment arm was omitted. 53 of 55 patients were evaluable. In group 1 (symptomatic therapy) results were better as to patients' quality of life, but no tumor remissions have been observed and survival times were significantly shorter (15 to 122 days; geometric mean 42.35 days). In group 2 (ifosfamide monotherapy) one total remission (lasting 15 months) and 2 partial remissions (lasting from 3 weeks to 4 months) have been achieved; in this group survival was 3 to 473 days (geometric mean 110.15 days). In group 3 (ifosfamide + CCNU) 7 partial remissions have been observed (3 weeks to 4 months), survival was 17 to 477 days (geometric mean 107.32 days). The combination of ifosfamide with CCNU did not reveal any advantage in comparison to ifosfamide monotherapy.
D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008130:Lomustine / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D011897:Random Allocation
D009607:Nitrosourea Compounds; D008130:Lomustine; D003520:Cyclophosphamide; D007069:Ifosfamide
Ifosfamid versus ifosfamid + CCNU in der Behandlung des inoperablen kleinzelligen Bronchuskarzinoms. Eine klinische Studie.